Micronase

/Home/Diabetes Treatment/Diabetes Drug Treatment/Glyburide (Glyburide)/Glyburide (Glyburide) Drug Interactions

Micronase
Diabetes and Foot Problems Slideshow Drug Description(glyburide) Tablets, USP 1.25, 2.5, and 5 mg

DRUG INTERACTIONS
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving MICRONASE, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving MICRONASE, the patient should be observed closely for loss of control.

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phe- nothiazines, thyroid products, estrogens, oral contra- ceptives, phenytoin, nicotinic acid, sympathomimet- ics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving MICRONASE, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving MICRONASE, the patient should be observed closely for hypoglycemia.

A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypo- glycemic action of glyburide. The mechanism for this interaction is not known.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this inter- action also occurs with the intravenous, topical or vaginal preparations of miconazole is not known.

Metformin: In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. The single-dose nature of this study and the lack of corre- lation between glyburide blood levels and pharmaco- dynamic effects, makes the clinical significance of this interaction uncertain. Coadministration of gly- buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco- dynamics.